218 related articles for article (PubMed ID: 23103525)
1. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.
Eibl JK; Strasser BC; Ross GM
Neurochem Int; 2012 Dec; 61(8):1266-75. PubMed ID: 23103525
[TBL] [Abstract][Full Text] [Related]
2. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management.
McKelvey L; Shorten GD; O'Keeffe GW
J Neurochem; 2013 Feb; 124(3):276-89. PubMed ID: 23157347
[TBL] [Abstract][Full Text] [Related]
3. Targeting nerve growth factor in pain: what is the therapeutic potential?
Watson JJ; Allen SJ; Dawbarn D
BioDrugs; 2008; 22(6):349-59. PubMed ID: 18998753
[TBL] [Abstract][Full Text] [Related]
4. Modulation of neurotrophin signaling by monoclonal antibodies.
Rosenthal A; Lin JC
Handb Exp Pharmacol; 2014; 220():497-512. PubMed ID: 24668485
[TBL] [Abstract][Full Text] [Related]
5. Nerve growth factor and its monocyte receptors are affected in kidney disease.
Antonucci MT; Bonofiglio R; Papalia T; Caruso F; Caroleo MC; Mancuso D; Aloe L
Nephron Clin Pract; 2009; 111(1):c21-8. PubMed ID: 19169037
[TBL] [Abstract][Full Text] [Related]
6. Novel class of pain drugs based on antagonism of NGF.
Hefti FF; Rosenthal A; Walicke PA; Wyatt S; Vergara G; Shelton DL; Davies AM
Trends Pharmacol Sci; 2006 Feb; 27(2):85-91. PubMed ID: 16376998
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of nerve growth factor-TrkA signaling and the relief of pain.
Mantyh PW; Koltzenburg M; Mendell LM; Tive L; Shelton DL
Anesthesiology; 2011 Jul; 115(1):189-204. PubMed ID: 21602663
[TBL] [Abstract][Full Text] [Related]
9. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.
Ugolini G; Marinelli S; Covaceuszach S; Cattaneo A; Pavone F
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2985-90. PubMed ID: 17301229
[TBL] [Abstract][Full Text] [Related]
10. Nerve growth factor and nociception: from experimental embryology to new analgesic therapy.
Lewin GR; Lechner SG; Smith ES
Handb Exp Pharmacol; 2014; 220():251-82. PubMed ID: 24668476
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance.
Wild KD; Bian D; Zhu D; Davis J; Bannon AW; Zhang TJ; Louis JC
J Pharmacol Exp Ther; 2007 Jul; 322(1):282-7. PubMed ID: 17431136
[TBL] [Abstract][Full Text] [Related]
12. Structural biology. The p75 NGF receptor exposed.
Zampieri N; Chao MV
Science; 2004 May; 304(5672):833-4. PubMed ID: 15131296
[No Abstract] [Full Text] [Related]
13. Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA.
Colquhoun A; Lawrance GM; Shamovsky IL; Riopelle RJ; Ross GM
J Pharmacol Exp Ther; 2004 Aug; 310(2):505-11. PubMed ID: 15051797
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain.
Woolf CJ
Philos Trans R Soc Lond B Biol Sci; 1996 Mar; 351(1338):441-8. PubMed ID: 8730783
[TBL] [Abstract][Full Text] [Related]
15. Nerve growth factor and the physiology of pain: lessons from congenital insensitivity to pain with anhidrosis.
Indo Y
Clin Genet; 2012 Oct; 82(4):341-50. PubMed ID: 22882139
[TBL] [Abstract][Full Text] [Related]
16. Differential endocytic sorting of p75NTR and TrkA in response to NGF: a role for late endosomes in TrkA trafficking.
Saxena S; Howe CL; Cosgaya JM; Steiner P; Hirling H; Chan JR; Weis J; Krüttgen A
Mol Cell Neurosci; 2005 Mar; 28(3):571-87. PubMed ID: 15737746
[TBL] [Abstract][Full Text] [Related]
17. Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.
Covaceuszach S; Marinelli S; Krastanova I; Ugolini G; Pavone F; Lamba D; Cattaneo A
PLoS One; 2012; 7(3):e32212. PubMed ID: 22403636
[TBL] [Abstract][Full Text] [Related]
18. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.
Halvorson KG; Kubota K; Sevcik MA; Lindsay TH; Sotillo JE; Ghilardi JR; Rosol TJ; Boustany L; Shelton DL; Mantyh PW
Cancer Res; 2005 Oct; 65(20):9426-35. PubMed ID: 16230406
[TBL] [Abstract][Full Text] [Related]
19. Nerve growth factor & TrkA as novel therapeutic targets in cancer.
Demir IE; Tieftrunk E; Schorn S; Friess H; Ceyhan GO
Biochim Biophys Acta; 2016 Aug; 1866(1):37-50. PubMed ID: 27264679
[TBL] [Abstract][Full Text] [Related]
20. Differential actions of nerve growth factor receptors TrkA and p75NTR in a rat model of epileptogenesis.
Li S; Saragovi HU; Nedev H; Zhao C; Racine RJ; Fahnestock M
Mol Cell Neurosci; 2005 Jun; 29(2):162-72. PubMed ID: 15911341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
